Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.55 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30903877 | 0.98 | CA12 (0.53) | CA12CA9UPP1CA1CA2 | |
| SCHEMBL19751500 | 0.74 | CA12 (0.46) | CA12CA9UPP1CA1CA2 | |
| SCHEMBL16050842 | 0.72 | CA12 (0.62) | CA12CA9CA1CA3CA4 | |
| SCHEMBL12778112 | 0.72 | DYRK1A (0.41) | CA1CA2MCL1HTTCLK1 | |
| SCHEMBL3224071 | 0.71 | CA12 (0.60) | CA12CA9CA1CA3CA4 | |
| SCHEMBL3137037 | 0.71 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| SCHEMBL4178782 | 0.71 | CA12 (1.00) | CA12CA9CA1CA3CA4 | |
| SCHEMBL29385308 | 0.71 | CA12 (0.60) | CA12CA9CA1CA3CA4 | |
| SCHEMBL30063823 | 0.71 | CA12 (0.60) | CA12CA9CA1CA3CA4 | |
| SCHEMBL433883 | 0.71 | CA12 (0.60) | CA12CA9CA1CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656143-B1 | NOVEL USE OF QUINOLONE ANTIBIOTICS | BAYER ANIMAL HEALTH GMBH (DE) | 2011-10-12 | — | — | EP | claimed |
| US-20070082911-A1 | Novel use of quinolone antibiotics | ELANCO ANIMAL HEALTH GMBH (DE) | 2007-04-12 | — | — | US | claimed |
| CN-108349899-A | The derivative of halogenated that rhzomorph of quinoline | 加利福尼亚大学董事会 | 2018-07-31 | — | — | CN | disclosed |
| US-8658645-B2 | Use of quinolone antibiotics | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| US-7867992-B2 | such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses | AICURIS GMBH & CO. KG (DE) | 2011-01-11 | — | — | US | disclosed |
| US-7569563-B2 | Substituted quinolones II | AICURIS GMBH & CO. HK (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20080261964-A1 | Substituted quinolones II | AICURIS GMBH & CO. KG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20070293478-A1 | Substituted quinolones | BAYER HEALTHCARE AG (DE) | 2007-12-20 | — | — | US | disclosed |
| US-20070082911-A1 | Novel use of quinolone antibiotics | ELANCO ANIMAL HEALTH GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| EP-1140850-A1 | QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6248739-B1 | DNA POLYMERASE INHIBITORS EFFECTIVE AGAINST HERPESVIRUSES | PHARMACIA & UPJOHN COMPANY | 2001-06-19 | — | — | US | disclosed |
| WO-2000040561-A1 | QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261964-A1 | Substituted quinolones II | TOP2A, TPMT, TOP2B | CA12 1959/4885CA9 2273/4885UPP1 568/4885 |
| US-20070082911-A1 | Novel use of quinolone antibiotics | QARS1, NQO2, DHX35 | CA12 3516/4885CA9 2589/4885UPP1 2629/4885 |
| US-20070293478-A1 | Substituted quinolones | IRF3, TPMT, NQO2 | CA12 2872/4885CA9 2725/4885UPP1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.